The ability of sorafenib to kill hepatoma cells was reduced by knock down of PDGFR and sorafenib (6 M) toxicity was suppressed by knock down of CD95 (Figure 4C). fashion, those of FAS ligand and CD95. Neutralization of FAS-L did not alter the initial quick drug-induced activation of CD95 however, neutralization of FAS-L reduced sorafenib + vorinostat toxicity by ~50%. Thus sorafenib contributes to CD95 activation by promoting receptor tyrosine phosphorylation whereas vorinostat contributes to CD95 activation via initial facilitation of ROS generation and subsequently of FAS-L expression. Keywords:Vorinostat, Sorafenib, CD95, c-FLIP-s, FAS-L, cell death, autophagy == Introduction == In the United States, hepatoma patients have a 5 12 months survival rates of less than 10% (1). We have recently developed a novel drug therapy combining the multi-kinase inhibitor Sorafenib with the histone deacetylase inhibitor vorinostat, and this combination is entering Homoharringtonine phase I trial in hepatoma (2-5). Sorafenib (Bay 43-9006, Nexavar; Homoharringtonine a RAF family kinase inhibitor) is a multi-kinase inhibitor that was originally developed as an inhibitor of RAF-1 but which was subsequently shown to inhibit multiple other kinases, including class III tyrosine kinase receptors (6). Anti-tumor effects of sorafenib in renal cell carcinoma and in hepatoma have been ascribed Homoharringtonine to anti-angiogenic actions of this agent through inhibition of the growth factor receptors (7-9). However, several groups, including ours, have shownin vitrothat sorafenib kills human leukemia cells at concentrations below the maximum achievable dose (Cmax) of 15-20 M, through a mechanism including down-regulation of MCL-1 (10,11). Sorafenib-mediated MCL-1 down-regulation occurred through a translational rather than a transcriptional or post-translational process that was mediated by endoplasmic reticulum (ER) stress signaling (12,13). This suggests that the previously observed anti-tumor effects of sorafenib are mediated by a combination of inhibition ofRAF familykinases and the ERK1/2 pathway; receptor tyrosine kinases that signal angiogenesis; and the induction of ER stress signaling. Histone deacetylase inhibitors (HDACI) represent a class of brokers that take action by blocking histone de-acetylation, thereby modifying chromatin structure and gene transcription. HDACs, along with histone acetyl-transferases, reciprocally regulate the acetylation status of the positively charged NH2-terminal histone tails of nucleosomes. HDACIs promote histone acetylation and neutralization of positively charged lysine residues on histone tails, allowing chromatin to presume a more open conformation, which favors transcription (14). However, HDACIs also induce acetylation of other nonhistone targets, actions that may have plieotropic biological effects, Homoharringtonine including inhibition of HSP90 function, induction of oxidative injury and up-regulation of death receptor expression (15-17). With respect to combinatorial drug studies with a multi-kinase inhibitor such as sorafenib, HDACIs are of interest in that they also Homoharringtonine down-regulate multiple oncogenic kinases by interfering with HSP90 function, leading to proteasomal degradation of these proteins. Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) is a hydroxamic acid HDACI that has shown preliminary pre-clinical evidence of activity in hepatoma and other malignancies with a Cmaxof ~9 M (18-28). We have recently published that sorafenib and vorinostat to interact to kill in a wide range of tumor cell types via activation of the CD95 extrinsic apoptotic pathway, concomitant with drug-induced reduced expression of c-FLIP-s via PERK/eIF2 activation (29,30). The present studies have extended in greater molecular detail our analyses to understanding how sorafenib and vorinostat individually interact to promote CD95 activation and tumor cell death. == Materials and Methods == == Materials == Sorafenib Rabbit Polyclonal to TACC1 tosylate (Bayer) and vorinostat (Merck) were provided by the Cancer Treatment and Evaluation Program, National Cancer Institute/NIH (Bethesda, MD). Trypsin-EDTA, DMEM, RPMI, penicillin-streptomycin were purchased from GIBCOBRL (GIBCOBRL Life Technologies, Grand Island, NY). HEPG2, HEP3B, HuH7 (hepatoma) cells.